Biogen's (BIIB) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $270.00 target price on the biotechnology company’s stock. Several other research analysts have also recently weighed in on the stock. Truist Financial reiterated a buy rating […]

Related Keywords

Germany , United States , Canada , Erick Rowinsky , Robertw Baird , Priya Singhal , Canaccord Genuity Group , Nasdaq , Rise Advisors , Royal Bank , Biogen Inc , Wells Fargo Company , Biogen Company Profile , Securities Exchange Commission , Kb Financial Partners , Free Report , Genuity Group , Moderate Buy , Stock Down , Get Free Report , Exchange Commission , Director Eric , Asset Management , Financial Advisory , Capital Management , Biogen Daily , Biogen , Nasdaq Biib , Biib , Medical , 09062x10 , Reiterated Rating , Oppenheimer Holdings Inc ,